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Purpose: Robotic Stereotactic Body Radiation Therapy with real-time tumor tracking has shown encouraging results
for hepatic tumors with good efficacy and low toxicity. We studied the factors associated with local control of
primary or secondary hepatic lesions post-SBRT.
Methods and materials: Since 2007, 153 stereotactic liver treatments were administered to 120 patients using the
CyberKnife® System. Ninety-nine liver metastases (72 patients), 48 hepatocellular carcinomas (42 patients), and six
cholangiocarcinomas were treated. On average, three to four sessions were delivered over 12 days. Twenty-seven
to 45 Gy was prescribed to the 80% isodose line. Margins consisted of 5 to 10 mm for clinical target volume (CTV)
and 3 mm for planning target volume (PTV).
Results: Median size was 33 mm (range, 5–112 mm). Median gross tumor volume (GTV) was 32.38 cm3 (range,
0.2–499.5 cm3). Median total dose was 45 Gy in three fractions. Median minimum dose was 27 Gy in three fractions.
With a median follow-up of 15.0 months, local control rates at one and two years were 84% and 74.6%,
respectively. The factors associated with better local control were lesion size < 50 mm (p = 0.019), GTV volume
(p < 0.05), PTV volume (p < 0.01) and two treatment factors: a total dose of 45 Gy and a dose–per-fraction of
15 Gy (p = 0.019).
Conclusions: Dose, tumor diameter and volume are prognostic factors for local control when a stereotactic
radiation therapy for hepatic lesions is considered. These results should be considered in order to obtain a
maximum therapeutic efficacy.
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Stereotactic body radiation therapy (SBRT) for hepatic
metastases (HM) and hepatocellular carcinoma (HCC)
has shown encouraging rates of local control and low
toxicity [1-4]. Many patients with primary or secondary
hepatic lesions can now be treated with these new tech-
niques. However relevant data and studies are still
required to define which patients will benefit best from
it and which fractionation regimen and total dose should* Correspondence: s-dewas @o-lambret.fr
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reproduction in any medium, provided the orbe used. Unfortunately, the published series are hetero-
geneous for the doses used as well as the number of
patients treated and do not allow for reliable analysis.
Since July 2007, a CyberKnife® System (Accuray Incorpo-
rated, Sunnyvale, California, U.S.A.) has been available in
our department. This image-guided system delivers hypo-
fractionated robotic SBRT. Herein, we present our results
for 153 primary or secondary hepatic lesions treated with
SBRT and the factors associated with tumor control.Materials and methods
Patients
Between July 2007 and March 2010, 120 patients under-
went SBRT with real-time tracking for primary orLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Dose constraints (for 3 to 4 fractions)
Organ Dose constraints
Liver V21 < 33%
Spinal cord Dmax < 22 Gy
Kidney V15 < 33%
Stomach V21 < 5 cm3
Duodenum V15 < 5 cm3
Dmax < 24 Gy
Small intestine V16 < 5 cm3
Dmax < 27 Gy
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treated for HM, 42 for HCC (36 patients with A and 6
patients with B Child-Pugh score) and six for cholangio-
carcinoma (CC).
Patients with HM were ineligible for hepatic surgery
or radiofrequency ablation. Other selection criteria for
HM were WHO score under 3, four or less hepatic
lesions and lesion size under 100 mm. For HCC, selec-
tion criteria were WHO score under 3, two or less
lesions, Child-Pughs score A or B. For cholangiocarci-
noma, selection criteria were WHO score under 2 and
target size under 120 mm. SBRT is considered for
patients for whom standard treatments such as resec-
tion, transplantation, chemoembolization or radiofre-
quency ablation were not feasible. Informed consent was
obtained in accordance with the guidelines of the French
National Cancer Institute (Institut National du Cancer)
required when assessing the efficacy and toxicity of a
novel therapy,
All treatments were delivered with the CyberKnife sys-
tem, at the Academic Department of Radiotherapy,
Centre Oscar Lambret, Lille. The population treated by
SBRT for hepatic tumors consisted of 120 patients (78
men and 42 women). The average age was 65 years
(range, 23 to 85 years). There were a total of 153 tumors;
97 patients had one, 15 patients two, six patients three,
and two patients had four tumors treated. The median
diameter of a tumor was 33 mm (range, 5 to 112 mm).
The median volume of GTV was 32.38 cm3 (range, 0.2
to 499.5 cm3).
Planning and treatment
The outpatient treatments were conducted using the
Multiplan® v3 treatment planning software (Accuray)
and the Synchrony® Respiratory Tracking System
(Accuray), enabling the tracking of tumor movement in
real time. Gold markers (fiducials) were implanted
around the lesion before the planning CT. Three to four
fiducials are implanted close to the target by a radiolo-
gist with a CT scan while the patient is under local
anesthesia. The median time between fiducial implant-
ation and the beginning of the treatment was 29 days
(minimum seven days). A triphasic (arterial phase, portal
phase, and late phase) planning CT scan was recorded
twice with 50 cc of iodinated contrast agent, 1- and 3-
mm slice thickness with the patient lying on a vacuum
mattress or a self-expanding foam mattress. Gross
Tumor Volume (GTV) was based on the better of either
the contrast-enhanced planning CT or MRI, depending
on image quality. Clinical Target Volume (CTV) was
5 mm geometric expansion of the GTV (CTV =GTV +
5 mm) to treat any microscopic disease extension. The
margin was 1 cm within the liver, and none outside, in
cases of HCC and CC. Planning Target Volume (PTV)contained the CTV and a 3-mm geometric margin to ac-
count for the uncertainty secondary to the slice thick-
ness. Two weeks were usually necessary between
dosimetric CT and start of treatment. The prescribed
dose was 45 Gy for HCC. Early HM cases received
40 Gy in four equal fractions; then the dose was
increased to 45 Gy in three equal fractions, as in the
cases of HCC. Dose constraints are shown in Table 1.
Doses slightly varied based on the location of the tumor
and the nearby organs at risk. Normal tissue constraints
used for liver lesions included the volume receiving
21 Gy (V21 < 33%) < 33% and V15 < 50% for normal
liver. If this constraint was not possible, dose was
decreased. The dose was prescribed to the 80% isodose
line (95% of the PTV receiving the total dose) and deliv-
ered in an average of eight days (range, four to 17 days).
Follow-up
All patients had a contrast-enhanced CT scan of the
thorax, abdomen, and pelvis, and a hepatic MRI when it
was available, at the time of treatment. Imaging was
repeated at each follow-up every three months in
addition to the clinical examinations and biochemical
tests. Evaluations took into account changes in tumor
vascularization, as recommended by EASL (European
Association for the Study of the Liver) [5]. Local
response was considered complete in case of disappear-
ance of the target lesion or its replacement by fibrotic
scar not changing in size or partial when at least a 30%
decrease in the largest diameter of the target was
observed. Failure was defined as an increase of at least
20% in the size of the largest axis of the target. Absence
of any of the above was considered stable disease includ-
ing any changes in vascularization determined by con-
trast intake. Local control was imaging-based absence
of progression. Follow-up was defined has the time
between last treatment session and last evaluation.
Statistics
The software STATA v11 (Stata Corporation, College
Station, Texas, USA) was used for the statistical analyses.
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the treatment (as opposed to first diagnosis) until pro-
gression. Rates were estimated using the Kaplan-Meier
method. Differences among survival curves were com-
pared using the log-rank test. The univariate analyses of
local control were performed using the Cox regression
model. Fisher exact test and Pearson chi-squares meth-
ods were used to study the association between cate-
gorical variables, and the Kruskal-Wallis test for
continuous variables. The Pearson correlation coefficient
was used to assess the association between two quantita-
tive variables. A p value <0.05 was chosen as the signifi-
cance threshold.Results
Patient and treatment characteristics
Patient characteristics are shown in Table 2. Median
tumor diameter was 33 mm (range, 5 to 112 mm);
median GTV was 32.38 cm3 (range, 0.2 to 499.5 cm3)
and median hepatic volume was 1,606 cm3 (range, 843
to 2,940 cm3). Dosimetric and technical data are pre-
sented in Table 3. Mean session length was 107 minutes
(range, 36 to 199 minutes); average number of beams
per treatment was 152 (range, 25 to 276 beams); median
total dose was 45 Gy (15 Gy per session); the lowest
total dose was 27 Gy (9 Gy per session); median follow-
up was 15.0 months (CI 95%: 12.4 to 17.5 months).Table 2 Patient characteristics




Male 78 (65%) 32 (76.2%
Female 42 (35%) 10 (23.8%
Age 67 (23–85) 69 (43–85
Weight (kg): 78 (43–120) 83 (47–12
BMI 26.1 (14.2–43.3) 29 (20.5–4
WHO
0 92 (77.3%) 31 (73.8%
1 23 (18.5%) 11 (26.2%
2 4 (3.4%) 0
3 1 (0.8%) 0
Prior treatments 114 (95%) 19 (45.2%
Radiofrequency 11 (9.2%) 2 (4.8%)
Surgery 31 (25.8%) 4 (9.5%)
Chemo–embo 8 (6.7%) 6 (14.3%)
Radiotherapy 2 (1.7%) 1 (2.4%)
Chemotherapy 62 (51.7%) 6 (14.3%)
Hepatic volume (cm3) 1548 (843–2940) 1614 (908
Targets size (Sum in mm per patient) 45 (8–159) 40(17–145
*Chi-square/Fisher exact or Kruskal-Wallis.Local control
Twenty-two patients showed progression of one or more
treated lesions (18.3%). Three patients with HCC (7.3%
of HCC cohort), 17 patients with HM (25.4% of HM
cohort) and two patients with cholangiocarcinoma
(33.3% of CC cohort) experienced failures. Median time
to recurrence for HCC patients was 3.71 months, com-
pared to 6.74 months for HM and 13.6 months for CC
(p = 0.075). Overall one and two-year local control rates
regardless of pathology were 80.4% (CI 95%: 70.1% to
87.5%) and 72.5% (CI 95%: 60.2 to 81.6%) respectively.
For HCC the estimated local control rates at one and two
years were 90.5%. For HM, the one and two year local
control rates were 73.3% and 67.4%, respectively. Based on
the number of tumors, among the 153 lesions (99 MH,
48 HCC, and six CC tumors) four HCC tumors (8.7%),
19 HM tumors (20.2%), and two CC tumors (33.3%) pro-
gressed at a median 3.7 months, eight months, and
13.6 months, respectively (Figure 1). The local control rate
regardless of pathology was 83.7%. Local control rates
regardless of primary at one and two years were 84% (CI
95%: 75.6% to 89.7%) and 74.6% (CI 95%: 63.7% to 82.7%),
respectively. For HCC, the rate was 88.9% at both one and
two years (CI 95%: 72.5 to 95.8%); for HM, these rates are
80.9% (CI 95%: 69.7 to 88.3%) at one year and 72.5% at two
years (CI 95%: 59.3 to 82%). For CC, local control rate were
100% at one year and two-year follow-up was not reached.
Median survival without local recurrence was not reached.rcinoma Hepatic metastases Cholangiocarcinoma p*
) 42 (58.3%) 4 (66.7%) 0.14
) 30 (41.7%) 2 (33.3%)
) 64 (23–83) 70 (62–78) 0.16
0) 74.5 (43–115) 73 (68–85) 0.07
0.6) 25.6 (14.2–43.3) 27.1 (23.5–32) 0.03
) 58 (81.7%) 3 (50%)
) 9 (12.7%) 2 (33.3%) 0.08
3 (4.2%) 1 (16.7%)
1 (1.4%) 0
) 66 (91.7%) 3 (50%) < 0.001
9 (12.5%) 0 0.38
24 (33.3%) 3 (50%) 0.003
2 (2.8%) 0 0.11
1 (1.4%) 0 0.87
54 (75%) 2 (33.3%) < 0.001
–2611) 1499 (843–2940) 1783 (1607–2018) 0,19
) 45 (8–159) 63 (36–112) 0,24
Table 3 Treatment characteristics
Total N (%) or
Median (range)
Hepatocarcinoma Hepatic metastases Cholangiocarcinoma p*
Sum of GTV volumes (cm3) 32.9 (0.2–499) 47.5 (1.4–499) 25.6 (0.2–245) 261 (8–371) 0.029
Ratio of the volume of GTV to the Liver 0.02 (0–0.32) 0.03 (0–0.3) 0.02 (0–0.2) 0.1 (0–0.2) 0.028
Ratio of the volume of PTV to the Liver 0.08 (0–0.38) 0.09 (0–0.38) 0.05 (0–0.37) 0.2 (0–0.3) 0.074
Session length (min) 107 (35–199) 107 (35–156) 107 (41–199) 100 (74–151) 0.831
Number of beams (median) 150 (25–276) 148 (29–254) 149 (25–276) 182 (105–226) 0.449
Total dose (Gy) 45 (27–45) 45 (27–45) 45 (27–45) 45 (29–45) 0.321
– 45 Gy: 15 Gy x 3 – 45 Gy: 15 Gy x 3 – 45 Gy: 15 Gy x 3
– 39 Gy: 13 Gy x 3 – 40 Gy: 10 Gy x 4 – 40 Gy: 10 Gy x 4
– 36 Gy: 12 Gy x 3 – 39 Gy: 13 Gy x 3 – 39 Gy: 13 Gy x 3
– 30 Gy: 15 Gy x 2 – 36 Gy: 12 Gy x 3
– 30 Gy: 10 Gy x 3 – 30 Gy: 10 Gy x 3
– 27 Gy: 9 Gy x 3
Dose per fraction (Gy) 15 (9–15) 15 (9–15) 15 (9–15) 15 (10–15) 0,026
*Chi-square/Fisher exact or Kruskal-Wallis.
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nostic factors of local control : factors included in the
univariate analysis were : target diameter, GTV, PTV,
total dose, dose per fraction, number of fractions and
session length. The results are presented in Table 4 andFigure 1 Local recurrence-free survival by target (A) (n = 153)
and according to type of lesion (B).Figure 2. Accordingly, PTV appeared to be linked to
local control Figure 3 (p = 0.014).
Median time to local recurrence in the target when the
dose was less than 45 Gy, or when the dose per fraction
was less than 15 Gy, was 28.6 months. Median time to re-
currence with higher doses was not reached (p = 0.019).
The recurrence rate for tumors with PTV >200 cc was




We observed a local control rate at one and two years
of 90.5%. In other series in the literature, rates of local
control vary from 65% to 100% (Table 5). The local
control rate is 100% for the four HCC and one CCTable 4 Univariate analysis of local control at one and
two years per target (n = 153)
Local control per
target at 1 year (%)
Local control per
target at 2 years (%)
p*
Total dose
= 45 Gy 92.3 (82.1 – 96.8) 79.1 (61.6 – 89.3)
< 45 Gy 72.0 (56.4 – 82.8) 66.5 (50.3 – 78.5) 0.019
Target diameter
> 50 mm 74.6 (54.6 – 86.8) 63.0 (39.8 – 79.3)
< 50 mm 87.5 (77.9 – 93.1) 78.8 (65.9 – 87.3) 0.019
GTV volumes
> 100 cc 81.8 (58.5 – 92.8) 62.3 (31.0 – 82.6)
< 100 cc 84.4 (74.9 – 90.5) 76.8 (64.9 – 85.0) 0.063
PTV volumes
> 200 cc 72.6 (50.3 – 86.2) 59.9 (35.3 – 77.7)
< 200 cc 87.2 (78.0 – 92.8) 79.0 (66.7 – 87.2) 0.014
* Log-rank test (CI at 95%).
Figure 2 Local control per target. Factors associated with better local control: a dose of 45 Gy (p = 0.019), target diameter <50 mm
(p = 0.019), a GTV <100 cc (p = 0.063) and a PTV <200 cc (p = 0.014).
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found a local control of 71.9% at a median follow-up
of 10.5 months [7]. SBRT for HCC has found a role
and been studied as a local salvage treatment afterFigure 3 Local recurrence-free survival according to target
diameter and PTV (p = 0.004).incomplete transarterial chemoembolization [8], as a
bridge towards transplantation [9] or for recurrence
treatment [10]. Each study found SBRT to be both a
feasible and promising treatment for patient without any
other treatment option.
Cholangiocarcinoma
Data on cholangiocarcinoma treated with SBRT is
scarce. A study published by Kopek et al. [11] reported
the results of SBRT for 27 patients with unresectable
cholangiocarcinoma. 45 Gy were administered in three
fractions. With a median follow-up of 5.4 years, the
median progression-free survival and overall survival
were 6.7 and 10.6 months respectively. Another study
found similar interesting results with a one-year local-
control rate of 100% [12]. However these studies had a
limited number of patients. Their results are compar-
able to the efficacy of fractionated chemoradiotherapy
for these poor-prognosis patients. SBRT could how-
ever be easier and faster to perform with less toxicity
for the patient.
Table 5 Published studies of stereotactic radiation therapy for hepatic lesions












at 1 and 2 years
Comments
Blomgren et al. 1998 [20] HCC and CC (n = 20) 41 30 2-3 22 cc/- 11 100% overall control Retrospective
HM (n = 21) 24 cc/- 95% overall control
Herfarth et al. 2001 [13] HCC + CC (n = 4) 37 14-26 1 10 cc/- - 67/- Phase I/II
HM (n = 56)
Fuss et al. 2004 [21] HCC (n = 1) 15 36 3-6 56 cc/- 6.5 94/- Retrospective
HM (n = 17)
Schefter et al. 2005 (27) HM (n = 18) 18 36-60 3 18 cc/- - - Phase I
Body Frame
Mendez et al. 2006 [22] HCC (n = 11) 25 25–37.5 3-5 22 cc/32 mm 12.9 (1.1–322) 94/82 Phase I/II
Body Frame75/75 (HCC)
HM (n = 34) 100/86
(HM)
Wulf et al. 2006 [6] HCC + CC (n = 5) 44 21-36 1-3 - 15 92/66 Phase I
Body FrameHM (n = 39)
Hoyer et al. 2006 [23] HM CRC (n = 44) 64 45 3 -/35 4.5 years -/79 Phase II
Body Frame
Kavanagh et al. 2006 [24] HM (n = 36) 36 60 3 14 cc/6 19 93% at 18 months Phase I/II
Body Frame
Katz et al. 2007 [25] HM (n = 174) 69 30-55 7-20 9.9 cc/27 mm 14.5 76/57 Retrospective
Exac Trac
Tse et al. 2008 [26] HCC + CC (n = 31 + 10) 41 24–54 6 173 cc 17.6 (10.8 – 39.2) 65% Phase I
Respiration control




Rusthoven et al. 2009 [15] HM (n = 63) 47 60 3 15 cc/27 mm 16 95/92 Phase I/II
Lee et al. 2009 [27] HM (n = 68) 68 27-60 6 75.2 cc/- 10.8 71/- Phase I
Respiration control
Ambrosino et al. 2009 [1] HM (n = 27) 27 25-60 3 69 cc/- 13 (6–16) 85.2% overall control Retrospective
CyberKnife
Goodman et al. 2009 [3] HCC + CC (n = 7) 26 18-30 1 33 cc/- 17.3 (2–55) 77/- Phase I
CyberKnifeHM (n = 19)


















Table 5 Published studies of stereotactic radiation therapy for hepatic lesions (Continued)
Body Frame
Cardenes et al. 2010 [28] HCC (n = 25. including 3 PT) 17 36-48 3 34 cc/40 mm 24 (10–42) 100% Phase I
CyberKnife
Present study 2010 153 120 27-45 2-4 73 cc/48 mm 15 (12–18) 80.4/72.5 Retrospective
CyberKnifeHCC (n = 48. including 3 PT) 42 27-45 2-3 87 cc/48 mm 13.7 90.5/90.5
73.3/67.4
HM (n = 99) 72 30-45 3-4 54 cc/47 mm 15.5 100/-
CC (n = 6) 6 39-45 3-4 208 cc/65 mm 11
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Regarding metastatic hepatic lesions in the literature, the
median follow-up ranges from six to 54 months. The
local control rate varies between 82% and 100%. At one
and two years, actuarial control rates range from 71% to
100% and from 64% to 86% The only prognostic factor
found is the dose, tumors receiving a lower dose having
a poorer local control.
Total dose as a major prognostic factor
One of the first prospective studies using stereotactic
radiotherapy as a single fraction with doses of 14–26 Gy
for the treatment of hepatic tumors, including HCC and
metastases, was conducted by Herfarth et al. [13]. The
actuarial local control rates were 75%, 71%, and 67% at
six-, 12-, and 18-months respectively. Updating these
results yielded a local control rate of 66% at 18 months
after a single fraction of 22 Gy [14]. The authors showed
that the reduction in tumor volume may be delayed after
a single irradiation dose; eight of the 17 patients with
stable disease at the first evaluation achieved a complete
or partial response at last follow-up. More recently,
Ambrosino et al. published their preliminary results of
SBRT by CyberKnife for unresectable hepatic lesions in
27 patients [1]. They obtained disease control in 74.1%
of cases. The latest study to our knowledge was by Van
der Pool et al. [4], reporting a local control rate of 74%
at two years, with the Body Frame system, after three
sessions of 12.5 Gy. Our results appear quite similar to
these studies, local control rates at one and two years
being 73.3% and 67.4%, respectively. The prescription
dose is very heterogeneous in these studies, making
comparison of the results difficult. The importance of
the dose in the treatment of hepatic metastases has
already been suggested. In the study by Herfarth, pro-
gression was observed in 12 of 55 tumors (22%) [13].
The difference in local tumor control between the group
receiving 20 to 26 Gy, compared with the group receiv-
ing 14 to 20 Gy, was statistically significant (p <0.001).
The diameter and the volume of the GTV and the PTV
were identified in our series as prognostic factors of local
control. The influence of the tumor size remains contro-
versial in the literature. According to Rusthoven et al.,
size plays a role in local control: lesions less than 3 cm
have a local control rate at two years of 100%, compared
to 77% for lesions greater than 3 cm (p = 0.0015) [15]. In
other series, stratification by size reveals no significant
difference in local control between lesions larger than
15 cm3 compared with lesions less than 15 cm3 in
patients treated with doses above 20 Gy [13].
In the literature, the treatment technique, dose, and
fractionation used vary from one study to the other. The
doses delivered range from 30 Gy in a single fraction to
54 Gy in six fractions of 9 Gy [6,7,16]. It has beendemonstrated that there is a dose–response relationship
for HCC with non-stereotactic conformal hepatic irradi-
ation with an increased response rate as the dose
increases [17,18]. The same relationship holds when
reproduced using the milimetric tracking accuracy of
CyberKnife. Our treatment regimen enables delivering a
total dose of 45 Gy in three fractions of 15 Gy. Accord-
ing to the quadratic linear model, the equivalent of this
dose in conventional fractionation of 2 Gy for an alpha/
beta ratio of 10 Gy would be 112.5 Gy. Regarding frac-
tionation, the regimens with a single session seem a little
less effective in terms of local control, especially those
using a low dose per fraction [13,17]. A recent study
reviewed 141 patients treated with hepatic and pulmon-
ary stereotactic radiation therapy, without distinction, in
order to find predictive factors of local control [16].
There were 246 lesions (165 lung cancers and 81
patients with hepatic lesions). The factors found in that
analysis were also, as in our series, the delivered dose
(p <0.001) and a tendency for the GTV (p = 0.064) in
multivariate analysis. In another study, the team of
Wada et al. demonstrated a role for target size in 24
patients treated for 42 lesions in both lung and hepatic
locations [19]. A lesion of less than 3 cm in diameter
was associated with better local control (p = 0.0022).
While many studies show the interest of SBRT for liver
tumors [20-28], most of them are retrospective or with a
limited number of patients. Dose regimens and delivery
techniques vary to a great extent between each of them.
A multicentric, randomized trial comparing SBRT to
surgery could be of great interest in this context.
Conclusion
Our experience including 120 patients, reported in this
work, is to our knowledge the largest series in the litera-
ture. Factors limiting the effectiveness of this treat-
ment presented in this work are: lesion diameter, the
volume of the tumor and of the PTV. A total dose of
45 Gy and 15 Gy per fraction is necessary for maximum
efficiency. There is a certain dose–response relationship
for HCC, as well as with HM, prompting a high dose
level as possible.
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